ArticleJournal of diabetes investigation2013
Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia.
Article in Journal of diabetes investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 37 citations in OpenAlex.
- Prevention of Cardiovascular Events with Pitavastatin is Associated with Increased Serum Lipoprotein Lipase Mass Level: Subgroup Analysis of the TOHO-LIP.Journal of atherosclerosis and thrombosis · 2022Trial
- CAVI-Lowering Effect of Pitavastatin May Be Involved in the Prevention of Cardiovascular Disease: Subgroup Analysis of the TOHO-LIP.Journal of atherosclerosis and thrombosis · 2021 · on this mapTrial
- Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial.EBioMedicine · 2018Trial
- Trial
- Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II.The Korean journal of internal medicine · 2017Trial
- Repurposing Pitavastatin and L-Glutamine: Replenishing β-Cells in Hyperlipidemic Type 2 Diabetes Mouse Model.Life (Basel, Switzerland) · 2023Article
- Current status of low-density lipoprotein cholesterol for primary prevention of coronary artery disease in late-stage elderly persons with type 2 diabetes mellitus: A retrospective, single-center study.Journal of diabetes investigation · 2022Article
- Real-World Analyses of the Safety Outcome among a General Population Treated with Statins: An Asian Population-Based Study.Journal of atherosclerosis and thrombosis · 2022Article
- Statin Intolerance Clinical Guide 2018.Journal of atherosclerosis and thrombosis · 2020Article
- Risk and Benefits of Statins in Glucose Control Management of Type II Diabetes.The International journal of angiology : official publication of the International College of Angiology, Inc · 2018Review
- Statins and risk for new-onset diabetes mellitus: A real-world cohort study using a clinical research database.Medicine · 2016 · on this mapObservational
- Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes.Journal of diabetes investigation · 2016 · on this mapArticle
- Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10?Current atherosclerosis reports · 2015Review
- Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.Cardiovascular diabetology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionThe distinct effects of different statins on glycemic control have not been fully evaluated. In this open-label, prospective, cross-over clinical trial, we compared the effects of pitavastatin and atorvastatin on glycemic control in type 2 diabetic patients with hypercholesterolemia. MATERIALS AND
methodsA total of 28 Japanese type 2 diabetics with hypercholesterolemia treated with rosuvastatin (2.5 mg/day) for at least 8 weeks were recruited to this quasi-randomized cross-over study. At study entry, the patients assigned to sequence 1 received pitavastatin (2 mg/day) for 12 weeks in period 1 and atorvastatin (10 mg/day) for another 12 weeks in period 2, whereas patients assigned to sequence 2 received atorvastatin (10 mg/day) for 12 weeks in period 1 and pitavastatin (2 mg/day) for another 12 weeks in period 2. Blood samples were collected at three visits (baseline, after 12 and 24 weeks).
resultsLipid control was similar in both statins. The difference in glycated hemoglobin between pitavastatin and atorvastatin treatments was -0.18 (95% confidence interval -0.34 to -0.02; P = 0.03). Compared with atorvastatin, pitavastatin treatment significantly lowered the levels of glycoalbumin, fasting glucose and homeostasis model assessment of insulin resistance.
conclusionsOur results showed that treatment with pitavastatin had a more favorable outcome on glycemic control in patients with type 2 diabetes compared with atorvastatin. This trial was registered with UMIN (no. 000003554).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.